-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OGVypPv4WzFj09n339e5g7oL4gtLZs/L5VR3zCIpZGnkeeFEKJHfy5agxq4l17EM RXGzV+mV1Feg0p3Ap5skyw== 0000913355-02-000083.txt : 20021002 0000913355-02-000083.hdr.sgml : 20021002 20021002150207 ACCESSION NUMBER: 0000913355-02-000083 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20021001 ITEM INFORMATION: Other events FILED AS OF DATE: 20021002 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DELCATH SYSTEMS INC CENTRAL INDEX KEY: 0000872912 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 061245881 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16133 FILM NUMBER: 02779697 BUSINESS ADDRESS: STREET 1: 1100 SUMMER ST 3RD FLOOR CITY: STAMFORD STATE: CT ZIP: 06905 BUSINESS PHONE: 2033238668 MAIL ADDRESS: STREET 1: 1100 SUMMER STREET CITY: STAMFORD STATE: CT ZIP: 06905 8-K 1 delcath8k100102.txt CURRENT REPORT DATED OCTOBER 1, 2002 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2002 DELCATH SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of (Commission File (IRS Employer incorporation) Number) Identification No.) 1100 Summer Street, Stamford, Connecticut 06905 (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (203) 323-8668 N/A (Former name or former address, if changed since last report) 5. Other Events and Regulation FD Disclosure On October 1, 2002, Delcath Systems, Inc. (the "Company") issued a press release announcing that its board of directors approved a stock repurchase program whereby the Company is authorized to repurchase a portion of its common stock. The Company's press release dated October 1, 2002 is incorporated herein by reference and filed as an exhibit hereto. Item 7. Financial Statements and Exhibits (a) Not applicable (b) Not applicable (c) Exhibits Exhibit No. Description 99 Press Release dated October 1, 2002 of Delcath Systems, Inc. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DELCATH SYSTEMS, INC. By: /s/ M. S. KOLY -------------------------------------- M. S. Koly President and Chief Executive Officer Date: October 2, 2002 3 EXHIBIT INDEX Exhibit No. Description 99 Press Release dated October 1, 2002 of Delcath Systems, Inc. EX-99 3 delcath8k100102ex99.txt PRESS RELEASE DATED OCTOBER 1, 2002 Exhibit 99 Contact: M.S. Koly Thomas Redington Chief Executive Officer Redington, Inc Delcath Systems, Inc. 203/222-7399 203/323-8668 212/926-1733 www.delcath.com www.redingtoninc.com DELCATH APPROVES STOCK REPURCHASE PROGRAM STAMFORD, CT OCT. 1 - Delcath Systems, Inc. (Nasdaq: DCTH) today announced that its board of directors approved a stock repurchase program whereby the company is authorized to repurchase a portion of its common stock. The board approved the repurchase by the company of up to 7 percent of its outstanding common stock at such times, at such prices and on such other terms as the president and chief executive officer approves. Under the board's authorization, the company is not obligated to repurchase any shares. Certain of the directors of the company have also indicated that they may purchase additional shares for their own account. Any purchases the company or its directors may make will depend on market conditions. Delcath's common stock is listed on the Nasdaq Small Cap Market and the Boston Stock Exchange under the symbols DCTH and DCT, respectively. Delcath, a development-stage company, is in the business of developing and marketing a proprietary drug delivery system capable of introducing, and removing, high-dose chemotherapy agents to a diseased organ system while greatly inhibiting their entry into the general circulatory system. # # # This release contains "forward-looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate. 10/1/02 -----END PRIVACY-ENHANCED MESSAGE-----